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in essential tremor byMRI-guided focused
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ABSTRACT
Objective: To report results of a prospective trial of unilateral transcranial MRI-guided focused
ultrasound (MRIgFUS) ablation of the cerebellothalamic tract in essential tremor (ET).
Methods: This was a prospective, uncontrolled, single-center interventional study. Patients with
ET fulfilling criteria for interventional therapy received unilateral ablation of the cerebellothalamic
tract (CTT) by MRIgFUS. Motor symptoms, manual dexterity, cognition, and quality of life were
assessed before intervention and at 48 hours and 1, 3, and 6 months after intervention. Rating
of standardized video recordings was blinded for evaluation time points. Primary outcomewas the
change in unilateral hand tremor score of the treated hand.
Results: Six patients received MRIgFUS ablation of the CTT contralateral to the treated hand.
Repeated-measures comparison determined a statistically significant 83% reduction (before vs 6
months after intervention mean6 SD; absolute reduction; 95% confidence interval) in the unilateral
treated hand subscore (14.3 6 4.9 vs 2.5 6 2.6; 11.8; 8.4–15.2; p , 0.001), while quality of life
improved by 52% (50.5 6 19.4 vs 24.8 6 11.4; 25.7; 3.5–47.28; p 5 0.046). Measures for
manual dexterity, attention and coordination, and overall cognition were unchanged. Transient side
effects (n 5 3) were ipsilateral hand clumsiness and mild gait instability for up to 3 months.
Conclusions: Unilateral MRIgFUS lesioning of the CTT was highly efficacious in reducing contra-
lateral hand tremor in ET without affecting fine motor function and dexterity over 6 months of
follow-up. Adverse effects were mild and transient.
Classification of evidence: This study provides Class IV evidence that for patients with ET, trans-
cranial MRIgFUS ablation of the cerebellothalamic tract improves tremor. Neurology®
2017;88:1329–1333
GLOSSARY
CTT 5 cerebellothalamic tract; DBS 5 deep brain stimulation; ET 5 essential tremor; MRIgFUS 5 MRI-guided focused
ultrasound; PSA 5 posterior subthalamic area; VIM 5 ventral intermediate.
The thalamic ventral intermediate (Vim) nucleus is part of the network involved in essential
tremor (ET) and the main stereotactic target for its treatment. It receives signals from the cer-
ebellar output nuclei via the cerebellothalamic tract (CTT).1 Both the high anatomic density of
CTT fibers before diverging within the Vim and its larger distance to sensory thalamic nuclei are
conceptual advantages of the CTT as a stereotactic target,1 acknowledged by neurosurgeons
performing subthalamotomies in the past.2 Deep brain stimulation (DBS) studies indicate that
the best stimulation effect on tremor is achieved in the white matter tracts caudal to the Vim
rather than the Vim itself.2,3 Recently, transcranial MRI-guided high-intensity focused ultra-
sound (MRIgFUS) has been established to induce thermal coagulation lesions through intact
skull and brain tissue under direct MRI guidance.4 We have adopted the long-standing idea of
subthalamotomy, i.e., CTT fiber tract ablation, for MRIgFUS treatment and report results from
a prospective study of unilateral transcranial CTT MRIgFUS ablation in ET.
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METHODS Standard protocol approvals, registrations,
and patient consent. This study was designed as a prospective,
uncontrolled, single-center interventional study, approved by
the ethics committee of St. Gallen, and conducted in
accordance with national and international law and good
clinical practice. All participants provided written informed
consent for participation.
The primary research question was to determine the efficacy
and safety of unilateral MRIgFUS ablation of the CTT in ET. Pa-
tients with a diagnosis of ET according to established criteria and
insufficient symptom control were included. Incision-less CTT
ablation was achieved with the ExAblate Neuro system. The tar-
get structure within the posterior subthalamic area (PSA) was
identified on 3T MRIs by a combination of direct targeting
and atlas-based5 coordinates. Interventions were performed as
described previously.4
At study visits before and 48 hours and 1, 3, and 6 months
after intervention, full neurologic examination, Clinical Rating
Scale for Tremors, Quality of Life in Essential Tremor, and man-
ual dexterity (9-hole peg test) were documented. Trail-Making
Test A and B were used as a combined measure for working mem-
ory, interference control, and visuomotor speed, and the Mini-
Mental State Examination and Montreal Cognitive Assessment
were used for cognitive screening.
Standardized tremor video recordings from all visits were rated
in random order and blinded for evaluation time point by a move-
ment disorder neurologist not involved in the treatments (S.R.S.).
Participants 4 and 5 were unavailable for evaluations at months 1
and 3 but attended all other time points. The primary endpoint
was change in hand tremor severity. Repeated-measures compari-
sons using mixed linear model statistics and least significant
difference post hoc test, as well as the Wilcoxon signed-rank
test, were calculated with SPSS version 22 (IBM, Armonk, NY)
(see supplemental data and figure e-1 at Neurology.org).
RESULTS The table summarizes interventional de-
tails of the participants who received unilateral MRIg-
FUS ablation of the CTT contralateral to the mainly
affected, treated hand. Postinterventional MRI con-
firmed exact lesion placement within the PSA (figure 1,
A–C), and there was no sign of bleeding on
susceptibility-weighted MRI. The initial mean lesion
size on T1-weighted images (156.9 6 63.5 mm3)
decreased rapidly over time (figure 1D).
Clinically, the intervention had an immediate
effect once a temperature .558C was reached (table).
There was a statistically significant, persisting reduc-
tion in Clinical Rating Scale for Tremors score over
the 6-month follow-up (repeated-measures statistics;
mean6 SD at baseline vs 6 months after intervention;
absolute reduction; 95% confidence intervals;
repeated measures statistics): overall sum (43.8 6
9.8 vs 19.8 6 6.8; 224.0; 218.1 to 229.9; p ,
0.001) and unilateral hand score on the treated side
Table Demographic and clinical patient characteristics, including treatment details
No.
Treated
hand Age, y
Disease
duration, y
Medication at
MRIgFUS
Target
coordinatesa
Maximum
applied energy, J
Sonications
administered, nb
Temperature
at first effect
on tremor, 8C
Peak
temperature,
8C
Duration,
minc
1 R 64 4 None 10/6.2/1 19,950 17 52 58 305
2 R 72 10 Propranolol 9/6/1 11,500 10 48 60 300
3 L 75 56 None 10/7.7/1.8 9,350 8 53 62 225
4 R 58 43 None 9.7/7.2/2 14,000 9 52 64 290
5 R 82 32 None 10.8/6.5/2.8 7,800 10 54 64 290
6 R 73 2 None 10.5/6.7/0 9,450 12 55 64 215
Mean 70.7 6 8.5 24.5 6 22.5 10/6.7/1.4 12,008 6 4,441 11 6 3.2 52.4 6 2.7 62.0 6 2.5 271 6 40
Abbreviation: MRIgFUS 5 MRI-guided focused ultrasound.
a Lateral/anterior–posterior/inferior of anterior commissure–posterior commissure plane (in millimeters).
b Lesion consolidation was attained by repeating the sonication that reached the peak temperature once more at unchanged settings.
c Time from local anesthesia to frame removal.
Figure 1 Lesion placement, size, and development over time
T1-weighted images showing the location and extent of the lesion in the posterior subthala-
mic area 2 days after MRI-guided focused ultrasound ablation in the axial (A), sagittal (B), and
coronal (C) planes. Volume changes during 6-month follow-up document the rapid decrease
in lesion volume, which is barely measurable from 3 months onward in most cases (D).
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(14.3 6 4.9 vs 2.5 6 2.6; 211.8; 28.4 to 215.2;
p , 0.001) (figure 2; see supplemental data for addi-
tional information).
Wilcoxon signed-rank (2-tailed) test showed
a significant 52% improvement in quality of life over
the same period (Quality of Life in Essential Tremor
Figure 2 Clinical effect of unilateral MRIgFUS ablation of the CTT
Six-month follow-up results of unilateral cerebellothalamic tract (CTT) MRI-guided focused ultrasound (MRIgFUS) lesion on
Clinical Rating Scale for Tremors (CRST) scores of the treated (A, B) and untreated (C) hand and overall tremor severity (D),
manual dexterity (E), fine motor tasks (F), cognition (G), and quality of life (H) in patients with advanced essential tremor.
QUEST 5 Quality of Life in Essential Tremor; TMT A 5 Trail-Making Test A.
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p5 0.046), whereas there were no significant changes
in manual dexterity (9-hole peg test) in the treated
and nontreated hand, concentration and fine motor
(Trail-Making Test A and B), and cognitive screening
(Mini-Mental State Examination, Montreal Cogni-
tive Assessment).
During the procedure, vestibular symptoms were
noted as immanently reversible side effects in 4 of 6
patients. They exclusively occurred during the final
sonications that delivered the highest acoustic power
per patient. After the procedure, subjective transient
clumsiness of the treated hand (n5 1) and gait insta-
bility (n 5 1) and objective tendency to veer to the
treated side (n 5 1) resolved within 3 months. No
dyskinesia emerged.
Patient 5 had an unwitnessed fall at home 4 weeks
after the intervention with an occipital fracture, intra-
cranial hematoma, and retrograde amnesia for the
event, necessitating hospitalization with eventual full
recovery. Retrospect analysis revealed an unexplained
fall 6 months before the intervention in this patient.
DISCUSSION This study is proof of principle that
the exact and safe MRIgFUS ablation of white
matter tracts within the PSA is potentially highly
effective in ET.
Similar to MRIgFUS ET studies that targeted the
Vim,6–8 there is immediate symptom suppression once
a thermal threshold is reached. Our data suggest that
thermal susceptibility and lesion volumetric changes
are similar between white matter tissue and previously
studied nuclear structures.6,7 We did not observe imag-
ing changes along white matter tracts outside the son-
ication target, indicating a confined local effect. In
humans, the CTT has been localized histologically1
and through advanced diffusion tensor imaging
in vivo3 within the PSA.2 By using a targeting approach
that combined atlas coordinates5 and individual ana-
tomic landmarks, we accommodated for the known
anatomic variability in the PSA, explaining minor de-
viations from mean literature PSA coordinates.2
Although these coordinates document that we aimed
at the PSA, only postmortem analysis would allow
ultimate target verification, as is true for all surgical
targets that cannot be readily identified on MRI.
Clinical data presented here suggest highly effica-
cious symptomatic relief of unilateral hand tremor by
contralateral CTT MRIgFUS ablation, as suggested
by retrospective data.9 The 83% efficacy in this study
is comparable to MRIgFUS Vim lesions in open-label
trials6 (75% after 12 months; n5 15), whereas a large
double-blind MRIgFUS Vim study8 reported a lower
efficacy rate (47% after 3 months, n5 76). In contrast
to studies aiming at the Vim nucleus,6,8 we observed no
transient or persistent paresthesia after CTT ablation,
possibly related to the larger anatomic distance of the
PSA to thalamic sensory structures. We provide evi-
dence that CTT MRIgFUS ablation does not worsen
manual dexterity and cognition, adding important
information to the safety profile of this intervention.
Converging evidence points to a central origin for
the fully reversible, intraprocedural vestibular symp-
toms observed by us and others6: Vim DBS for ET
can affect vestibulothalamic pathways.10 The steep
gradient of acoustic energy of MRIgFUS also limits
relevant effects to structures in the focus vicinity.
The transient, mostly subclinical ipsilateral cerebel-
lar side effects observed in part of our cohort are
most likely a direct effect on the CTT or adjacent
fiber tracts, as previously shown in PSA DBS.3 These
observations warrant cerebellar and vestibular mon-
itoring in future trials.
After careful evaluation, we do not think that the fall
in participant 5 is causally related to the study proce-
dure. The timing of the event and video-documented
gait and postural control examination before and after
intervention do not indicate any balance changes due
to the intervention. Nevertheless, preintervention gait
instability requires careful risk-benefit evaluation before
PSA MRIgFUS ablation.
Larger trials with a longer follow-up are needed to
adequately assess the long-term safety and efficacy of
MRIgFUS CTT ablation. Meanwhile, our study
backs the growing evidence for the efficacy of MRIg-
FUS ablation in ET and adds the CTT (Class IV evi-
dence) as a suitable target.
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